Case Study: In-License P&MA Assessment in Migraine
Project Objective
-
A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines
-
Windrose was asked to carry out due diligence on the value, price and market access potential of the new anti-CGRP to inform decision-making, including options to address potential competitor strategies
Windrose Approach
-
We assessed the current migraine pricing and market access landscape across the US, Europe, and Japan, and potential changes given entrance of multiple anti-CGRPs
-
We reviewed potential analogs to hypothesize payer outcomes for the client’s product.
-
We conducted in-depth interviews with national and regional payers & KOLs to assess key value drivers and barriers for the anti-CGRP competitors
-
In the US, we provided recommendations on the level of rebates required to maximize revenue
-
Identified price and utilization tradeoffs, when considering potential payer restrictions and level of patient copay
-
Evaluated impact on volume / prescribing if competitor attempts to undercut on price
-
Potential Price Strategies
Impact
-
Our recommendations helped to inform whether the client should enter a partnership with one of the companies developing an anti-CGRP
-
The client proceeded with an optimized pricing strategy and early payer engagement strategies to facilitate pricing / contracting discussion and improve access